Literature DB >> 23532754

Candida albicans and non-C. albicans Candida species: comparison of biofilm production and metabolic activity in biofilms, and putative virulence properties of isolates from hospital environments and infections.

A V Ferreira1, C G Prado, R R Carvalho, K S T Dias, A L T Dias.   

Abstract

Candida albicans and, more recently, non-C. albicans Candida spp. are considered the most frequent fungi in hospitals. This study analyzed Candida spp. isolates and compared the frequency of different species, that is, C. albicans and non-C. albicans Candida spp., and the origins of isolates, that is, from hospital environments or infections. Yeast virulence factors were evaluated based on biofilm production and metabolic activity. Hemolysin production and the antifungal susceptibility profiles of isolates were also evaluated. Candida spp. were highly prevalent in samples collected from hospital environments, which may provide a reservoir for continuous infections with these yeasts. There were no differences in the biofilm productivity levels and metabolic activities of the environmental and clinical isolates, although the metabolic activities of non-C. albicans Candida spp. biofilms were greater than those of the C. albicans biofilms (p < 0.05). Clinical samples had higher hemolysin production (p < 0.05) and lower susceptibility to fluconazole (p < 0.05). Non-C. albicans Candida spp. predominated in samples collected from hospital environments and infections (p < 0.05). These species had a lower susceptibility to fluconazole and amphotericin B, and their biofilms had higher metabolic activities than those produced by C. albicans, which may explain the increased incidence of fungal infections with these yeasts during recent years.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23532754     DOI: 10.1007/s11046-013-9638-z

Source DB:  PubMed          Journal:  Mycopathologia        ISSN: 0301-486X            Impact factor:   2.574


  31 in total

Review 1.  [Epidemiology of hematogenous infections due to Candida spp].

Authors:  Arnaldo Lopes Colombo; Thaís Guimarães
Journal:  Rev Soc Bras Med Trop       Date:  2003-10-21       Impact factor: 1.581

2.  Biofilm formation by five species of Candida on three clinical materials.

Authors:  D Estivill; A Arias; A Torres-Lana; A J Carrillo-Muñoz; M P Arévalo
Journal:  J Microbiol Methods       Date:  2011-06-12       Impact factor: 2.363

3.  In vitro biofilm activity of non-Candida albicans Candida species.

Authors:  Sónia Silva; Mariana Henriques; Rosário Oliveira; David Williams; Joana Azeredo
Journal:  Curr Microbiol       Date:  2010-04-17       Impact factor: 2.188

4.  Community-onset candidemia at a university hospital, 1995-2005.

Authors:  Hsiang-Chi Kung; Jiun-Ling Wang; Shan-Chwen Chang; Jann-Tay Wang; Hsin-Yun Sun; Po-Ren Hsueh; Yee-Chun Chen
Journal:  J Microbiol Immunol Infect       Date:  2007-08       Impact factor: 4.399

Review 5.  The significance of iron in infection.

Authors:  J J Bullen
Journal:  Rev Infect Dis       Date:  1981 Nov-Dec

Review 6.  Candida infections of medical devices.

Authors:  Erna M Kojic; Rabih O Darouiche
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

7.  A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients.

Authors:  Peter G Pappas; John H Rex; Jeannette Lee; Richard J Hamill; Robert A Larsen; William Powderly; Carol A Kauffman; Newton Hyslop; Julie E Mangino; Stanley Chapman; Harold W Horowitz; John E Edwards; William E Dismukes
Journal:  Clin Infect Dis       Date:  2003-08-14       Impact factor: 9.079

8.  [Candidemia in a Brazilian tertiary care hospital: incidence, frequency of different species, risk factors and antifungal susceptibility].

Authors:  João Cesar Beenke França; Clea Elisa Lopes Ribeiro; Flávio de Queiroz-Telles
Journal:  Rev Soc Bras Med Trop       Date:  2008 Jan-Feb       Impact factor: 1.581

9.  Distribution of Candida species in different clinical samples and their virulence: biofilm formation, proteinase and phospholipase production: a study on hospitalized patients in southern India.

Authors:  Vinitha Mohandas; Mamatha Ballal
Journal:  J Glob Infect Dis       Date:  2011-01

10.  Contamination, disinfection, and cross-colonization: are hospital surfaces reservoirs for nosocomial infection?

Authors:  Bala Hota
Journal:  Clin Infect Dis       Date:  2004-09-27       Impact factor: 9.079

View more
  20 in total

Review 1.  Candida identification: a journey from conventional to molecular methods in medical mycology.

Authors:  Mohammad Zubair Alam; Qamre Alam; Asif Jiman-Fatani; Mohammad Amjad Kamal; Adel M Abuzenadah; Adeel G Chaudhary; Mohammad Akram; Absarul Haque
Journal:  World J Microbiol Biotechnol       Date:  2014-01-01       Impact factor: 3.312

2.  2,5-Dimethyl-4-hydroxy-3(2H)-furanone as an Anti-biofilm Agent Against Non-Candida albicans Candida Species.

Authors:  Suganthi Martena Devadas; Usha Y Nayak; Reema Narayan; Manjunath H Hande; Mamatha Ballal
Journal:  Mycopathologia       Date:  2019-06-11       Impact factor: 2.574

Review 3.  How much do we know about hemolytic capability of pathogenic Candida species?

Authors:  Márcia C Furlaneto; Helena P Góes; Hugo F Perini; Renan C Dos Santos; Luciana Furlaneto-Maia
Journal:  Folia Microbiol (Praha)       Date:  2018-01-15       Impact factor: 2.099

Review 4.  Candidiasis: predisposing factors, prevention, diagnosis and alternative treatment.

Authors:  Natália Martins; Isabel C F R Ferreira; Lillian Barros; Sónia Silva; Mariana Henriques
Journal:  Mycopathologia       Date:  2014-05-01       Impact factor: 2.574

5.  In vitro antibiofilm efficacy of farnesol against Candida species.

Authors:  Mihrinur Yapıcı; Bükay Yenice Gürsu; İlknur Dağ
Journal:  Int Microbiol       Date:  2021-02-18       Impact factor: 2.479

6.  Activity of Sanguinarine against Candida albicans Biofilms.

Authors:  Hua Zhong; Dan-Dan Hu; Gan-Hai Hu; Juan Su; Shuang Bi; Zhuo-Er Zhang; Zheng Wang; Ri-Li Zhang; Zheng Xu; Yuan-Ying Jiang; Yan Wang
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

7.  Streptomyces: Derived Active Extract Inhibits Candida albicans Biofilm Formation.

Authors:  Sheng-Qiang Yang; Hui-Jie Zhou; Li-Ping Teng; Hong Zeng
Journal:  Curr Microbiol       Date:  2022-09-25       Impact factor: 2.343

8.  The calcium channel blocker verapamil inhibits oxidative stress response in Candida albicans.

Authors:  Qilin Yu; Chenpeng Xiao; Kailun Zhang; Chang Jia; Xiaohui Ding; Bing Zhang; Yu Wang; Mingchun Li
Journal:  Mycopathologia       Date:  2014-02-28       Impact factor: 2.574

9.  In Vivo Applicability of Neosartorya fischeri Antifungal Protein 2 (NFAP2) in Treatment of Vulvovaginal Candidiasis.

Authors:  Renátó Kovács; Jeanett Holzknecht; Zoltán Hargitai; Csaba Papp; Attila Farkas; Attila Borics; Lilána Tóth; Györgyi Váradi; Gábor K Tóth; Ilona Kovács; Sandrine Dubrac; László Majoros; Florentine Marx; László Galgóczy
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

10.  Effects of magnolol and honokiol on adhesion, yeast-hyphal transition, and formation of biofilm by Candida albicans.

Authors:  Lingmei Sun; Kai Liao; Dayong Wang
Journal:  PLoS One       Date:  2015-02-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.